- Home
- HYPR vs ACRV Comparison
HYPR vs ACRV Comparison
Compare HYPR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | ACRV |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 95.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | HYPR | ACRV |
|---|---|---|
| Price | $1.22 | $2.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $1.28 | ★ $13.00 |
| AVG Volume (30 Days) | 597.6K | ★ 3.3M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,591,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $35.44 | $805.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $1.05 |
| 52 Week High | $2.22 | $8.00 |
Technical Indicators
Market Signals| Indicator | HYPR | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 63.39 | 45.66 |
| Support Level | $0.95 | $1.57 |
| Resistance Level | $1.31 | $3.56 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 79.34 | 22.36 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.